BICO has published Annual Report 2021 for the financial year which covers January 1 to December 31, 2021. The Annual Report is available on BICO’s website: www.bico.com/investors. The printed version of the Annual Report 2021 will be available from the beginning of April.

For further information, please contact:
Gusten Danielsson, EVP and CFO

Phone (US): +1 (857) 332 2138

Phone (Sweden): +46 70 991 86 04     
Email:
gd@bico.com

This is information that BICO is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication on March 16, 2022, at 16:00 (CET).

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.

The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.  

The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

Contact us!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.